Phase II Study of Stereotactic Body Radiotherapy Combined With Chemotherapy for Stage III Non-Small Cell Lung Cancer with Tumors Up to 6 cm

What this Trial Is About

Researchers are studying stage III non-small cell lung cancer NSCLC to evaluate the feasibility and control of local tumor growth by combining high precision stereotactic body radiotherapy SBRT with chemotherapy. This study aims to improve outcomes for patients with tumors or lymph nodes measuring 6 centimeters or less. The trial builds on evidence that SBRT delivers high doses of targeted radiation with limited toxicity and may improve local control compared to conventional radiotherapy. The treatment being evaluated is SBRT administered to the primary tumor and involved lymph nodes in stage III NSCLC when the tumor size is 6 centimeters or smaller. SBRT delivers high dose radiation in few fractions with sharp dose gradients to minimize damage to surrounding tissues. The study will assess the efficacy and safety of SBRT combined with chemotherapy and monitor outcomes over two years. Participants will be involved in long-term follow-up to track tumor control, survival, toxicity, and quality of life. Assessments include imaging, toxicity grading, and quality of life questionnaires over a two-year period. The primary outcome measured is loco-regional control at two years, with secondary outcomes including disease-free survival, overall survival, toxicity, and quality of life. The study provides close monitoring and aims to evaluate the potential benefits and risks of this treatment approach.

A Phase II Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer